BioCatalystWatch
INMWorkspace / INM / OverviewCompany library
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. (INM)

Website

Price
Market cap
Next catalystInitial Phase 1 data expected mid-2027MT-001 — ongoing Phase 1 · Phase 1 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

MT-001

PACAP

PreINDP1P3FilingApproved
Upcoming / outlook

MT-002

CGRP × PACAP

PreINDP2P3FilingApproved
Upcoming / outlook

MT-001

PACAP

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

MT-002

CGRP × PACAP

PreINDP2P3FilingApproved
Upcoming / outlook

MT-001

PACAP

PreINDP1P3FilingApproved
Upcoming / outlook

MT-001

PACAP

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

CB1 × CB2

CB1 × CB2

CB1 × CB2

PreINDP1P2P3FilingApproved

CB1 × CB2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

INM PR & News

PR & News

INM SEC archive